CAJ | 학술논문

背景：细胞因子诱导的杀伤细胞作为一种有效的过继免疫治疗方法，成为治疗急性髓系白血病的一种新的手段，目前关于急性髓系白血病自体移植后序贯细胞因子诱导的杀伤细胞治疗的报道尚少，值得进一步研究。 　　目的：观察急性髓系白血病 M2患者自体外周血造血干细胞移植后序贯细胞因子诱导的杀伤细胞治疗的临床疗效和不良反应。 　　方法：入选45例低、中危急性髓系白血病M2患者，其中19例在自体外周血造血干细胞移植后序贯了细胞因子诱导的杀伤细胞治疗，另26例未序贯细胞因子诱导的杀伤细胞治疗，比较两组患者的复发率、无病生存率、总生存率，观察细胞因子诱导的杀伤细胞治疗的安全性。 　　结果与结论：①序贯细胞因子诱导的杀伤细胞治疗组的复发率低于未序贯细胞因子诱导的杀伤细胞治疗组(21.05%，38.46%，P<0.05)；序贯细胞因子诱导的杀伤细胞治疗组患者的2年无病生存率和2年总生存率均高于未序贯细胞因子诱导的杀伤细胞治疗组，差异均有显著性意义(P<0.05)。②19例接受细胞因子诱导的杀伤细胞治疗的患者均顺利完成治疗方案，治疗过程中除4例出现寒战、发热外，无其他不良反应。结果显示低、中危急性髓系白血病 M2患者自体外周血造血干细胞移植后序贯细胞因子诱导的杀伤细胞治疗可降低原发病的复发率，提高患者的无病生存率及总生存率，且无明显不良反应，是一种安全、有效、可行的治疗方法。
배경：세포인자유도적살상세포작위일충유효적과계면역치료방법，성위치료급성수계백혈병적일충신적수단，목전관우급성수계백혈병자체이식후서관세포인자유도적살상세포치료적보도상소，치득진일보연구。 　　목적：관찰급성수계백혈병 M2환자자체외주혈조혈간세포이식후서관세포인자유도적살상세포치료적림상료효화불량반응。 　　방법：입선45례저、중위급성수계백혈병M2환자，기중19례재자체외주혈조혈간세포이식후서관료세포인자유도적살상세포치료，령26례미서관세포인자유도적살상세포치료，비교량조환자적복발솔、무병생존솔、총생존솔，관찰세포인자유도적살상세포치료적안전성。 　　결과여결론：①서관세포인자유도적살상세포치료조적복발솔저우미서관세포인자유도적살상세포치료조(21.05%，38.46%，P<0.05)；서관세포인자유도적살상세포치료조환자적2년무병생존솔화2년총생존솔균고우미서관세포인자유도적살상세포치료조，차이균유현저성의의(P<0.05)。②19례접수세포인자유도적살상세포치료적환자균순리완성치료방안，치료과정중제4례출현한전、발열외，무기타불량반응。결과현시저、중위급성수계백혈병 M2환자자체외주혈조혈간세포이식후서관세포인자유도적살상세포치료가강저원발병적복발솔，제고환자적무병생존솔급총생존솔，차무명현불량반응，시일충안전、유효、가행적치료방법。
BACKGROUND:Cytokine induced kil er cells therapy as an effective means of adoptive immunotherapy, becomes a new way to treat acute myeloid leukemia. But, the researches about sequential cytokine induced kil er cells therapy after autologous peripheral blood stem celltransplantation in acute myeloid leukemia patients are stil less, which deserve further research. OBJECTIVE:To observe the clinical efficiency and safety of sequential cytokine induced kil er cells therapy after autologous peripheral blood stem celltransplantation in acute myeloid leukemia M2 patients. METHODS:Total y 45 patients with low-or intermediate-risk acute myeloid leukemia M2 were recruited in this study. Among them, 19 patients received sequential cytokine induced kil er cells therapy after autologous peripheral blood stem celltransplantation and 26 patients only received autologous peripheral blood stem celltransplantation. The relapse rate, disease-free survival, and overal survival were compared between two groups, and safety of cytokine induced kil er cells therapy was observed. RESULTS AND CONCLUSION:(1) Compared with the patients only receiving autologous peripheral blood stem celltransplantation, the relapse rate was lower (21.05%vs. 38.46%;P<0.05), and elevated percentages of the disease-free survival and overal survival were observed in the patients receiving sequential cytokine induced kil er cells therapy after autologous peripheral blood stem celltransplantation (P<0.05). (2) The 19 patients who received sequential cytokine induced kil er cells therapy after autologous peripheral blood stem celltransplantation al completed the treatment scheme successful y. Only four patients appeared to have chil s and fever, and no more side effects were observed. These findings suggested that the sequential cytokine induced kil er cells therapy after autologous peripheral blood stem celltransplantation can improve the disease-free survival and overal survival of low-or intermediate-risk acute myeloid leukemia M2 patients without remarkable side effects, which is a safe, effective and feasible way for the treatment of acute myeloid leukemia M2.